A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Members of some Christian sects in the Southern United States are regularly bitten while participating in "snake handling" rituals. Snake handling is when people hold venomous snakes, unprotected, as part of a religious service inspired by a literal interpretation of the Bible verses Mark 16:17–18, which reads, "In my name ... They shall take up serpents ...."
=== Commander in Sichuan === After graduation, Liu Wenhui returned to Sichuan. There, Liu rejected an offer by fellow Baoding graduate Deng Xihou to serve under him. Instead, he met with his older nephew Liu Xiang, who recommended him to warlord Liu Cunhou of the Sichuan Army. Liu became a staff officer in Liu Cunhou's army, but before long, he had been transferred by Liu Xiang to the Eighth Division under General Chen Hongfan, stationed in Leshan. He was promoted rapidly from battalion commander to brigade commander over a period of five years from 1917 to 1922 due to the patronage of Liu Xiang. By 1919, he, along with his close friend Leng Yindong commanded around half of Chen's forces. His performance in the 1919-20 war to expel Yunnanese forces from Sichuan earned him the attention of Liu Chengxun, who promoted him. This caused tensions with Chen Hongfan, and Liu was subsequently forced to flee to Qingshen. The two would later reconcile, and Chen appointed Liu as a commander in the Yibin area. Yibin, at the confluence of the Jinsha and Min rivers, was known as a major trade port. Around the time of the anti-Yunnan campaign, Liu's parents died, and Liu was unable to return home for their funerals. In 1922, Liu Wenhui became a brigade commander at Yibin with his nephew Liu Xiang's help. This move gave him total control over the city. To collect more funds, Liu brought in his brother, Liu Wencai, as an economic official.
There are three types of non-medical therapies, namely shielding by external protectors, light therapy and acupuncture. Bacterial invasion can be successfully blocked by external protectors of the nipple such as nipple shield, polyethylene film and silver cap, especially when the nipple is impaired by trauma. These protectors create a humid environment for wound recovery while defending it against bacterial infections. The silver cap consists of silver which is a natural agent with antibacterial properties. Hence it is also less likely to cause irritation. Light therapy including phototherapy and low-intensity laser therapy can treat nipple trauma as well. In the range of 630 to 1000 nm wavelength, light therapy facilitates wound recovery by promoting fibroblast proliferation, collagen synthesis, angiogenesis and growth factor production. Moreover, it can stimulate tissue regeneration, accelerate local blood flow rate through vasodilation, suppress inflammation, increase fissure healing rate, and reduce pain sensation. Recently, many review articles have suggested the effectiveness of acupuncture in treating nipple pain as it showed considerable improvement in treating breast engorgement. A 2016 Cochrane review found that a number of interventions were somewhat effective, such as hot/cold packs, Gua-Sha (scraping therapy), cabbage leaves, and proteolytic enzymes but none of the evidence supported widespread implementation.
Sources: en.wikipedia.org
Beyond its store endeavors, Jollibee also ventured into media, notably partnering with GMA for the children's magazine show Chikiting Patrol, which aired from 1996 to 2002. In 1998, Jollibee would expand to North America with its first United States location in Daly City, California. Jollibee first entered Europe in 2018 with the opening of a branch in Milan, Italy.
Representative James Talarico legislative website Talarico for Texas U.S. Senate campaign website Financial information (federal office) at the Federal Election Commission Profile at Vote Smart Appearances on C-SPAN
The likeness of the spectra of these three gases with those of argon, krypton, and xenon, and their observed chemical inertia led Sir William Ramsay to suggest in 1904 that the "emanations" might contain a new element of the noble-gas family. In 1909, Ramsay and Robert Whytlaw-Gray isolated radon and determined its melting temperature and critical point. Because it does not conform to expected periodic trends, their obtained melting point (the only experimental value) was questioned in 1925 by Friedrich Paneth and E. Rabinowitsch, but ab initio Monte Carlo simulations from 2018 agree almost exactly with Ramsay and Gray's result. In 1910, they determined its density (that showed it was the heaviest known gas) and its position in the periodic table. They wrote that "L'expression l'émanation du radium est fort incommode" ("the expression 'radium emanation' is very awkward") and suggested the new name niton (Nt) (from Latin: nitens, shining) to emphasize the radioluminescence property, and in 1912 it was accepted by the International Commission for Atomic Weights. In 1923, the International Committee for Chemical Elements and International Union of Pure and Applied Chemistry (IUPAC) chose the name of the most stable isotope, radon, as the name of the element. The isotopes thoron and actinon were later renamed 220Rn and 219Rn. This has caused some confusion in the literature regarding the element's discovery as while Dorn had discovered radon the isotope, he was not the first to discover radon the element.
Cell surface receptors play an essential role in the biological systems of single- and multi-cellular organisms and malfunction or damage to these proteins is associated with cancer, heart disease, and asthma. These trans-membrane receptors are able to transmit information from outside the cell to the inside because they change conformation when a specific ligand binds to it. There are three major types: Ion channel linked receptors, G protein–coupled receptors, and enzyme-linked receptors.
Sources: en.wikipedia.org
The Romanowsky stains is considered a polychrome staining effect and is based on a combination of eosin plus (chemically reduced eosin) and demethylated methylene blue (containing its oxidation products azure A and azure B). This stain develops varying colors for all cell structures (“Romanowsky-Giemsa effect) and thus was used in staining neutrophil polymorphs and cell nuclei. Common variants include Wright's stain, Jenner's stain, May-Grunwald stain, Leishman stain and Giemsa stain. All are used to examine blood or bone marrow samples. They are preferred over H&E for inspection of blood cells because different types of leukocytes (white blood cells) can be readily distinguished. All are also suited to examination of blood to detect blood-borne parasites such as malaria.
== Preparation == Since its first description in 1953, ethylene carbonate has been commonly used as starting material for vinylene carbonate. In the first stage, monochlorethylene carbonate is produced in a UV-initiated photochlorination reaction with chlorine or sulfuryl chloride at 60-70 °C in bulk. In the second stage, monochlorethylenecarbonate undergoes dehydrochlorination with a base such as triethylamine.
== Nomenclature == In addition to the IUPAC numbering system to differentiate the various carbons in an organic molecule, by sequentially assigning a number to each carbon, including those forming a carboxylic group, the carbons along the side-chain of amino acids can also be labelled with Greek letters, where the α-carbon is the central chiral carbon possessing a carboxyl group, a side chain and, in α-amino acids, an amino group – the carbon in carboxylic groups is not counted. (Consequently, the IUPAC names of many non-proteinogenic α-amino acids start with 2-amino- and end in -ic acid.)
The following table summarizes several budgetary statistics for the fiscal year 2015-2021 periods as a percent of GDP, including federal tax revenue, outlays or spending, deficits (revenue – outlays), and debt held by the public. The historical average for 1969-2018 is also shown. With U.S. GDP of about $21 trillion in 2019, 1% of GDP is about $210 billion. Statistics for 2020-2022 are from the CBO Monthly Budget Review for FY 2022.
The ELISA was the first screening test widely used for HIV because of its high sensitivity. In an ELISA, a person's serum is diluted 400 times and applied to a plate to which HIV antigens are attached. If antibodies to HIV are present in the serum, they may bind to these HIV antigens. The plate is then washed to remove all other components of the serum. A specially prepared "secondary antibody"—an antibody that binds to other antibodies—is then applied to the plate, followed by another wash. This secondary antibody is chemically linked in advance to an enzyme. Thus, the plate will contain enzyme in proportion to the amount of secondary antibody bound to the plate. A substrate for the enzyme is applied, and catalysis by the enzyme leads to a change in color or fluorescence. ELISA results are reported as a number; the most controversial aspect of this test is determining the "cut-off" point between a positive and a negative result. A cut-off point may be determined by comparing it with a known standard. If an ELISA test is used for drug screening at workplace, a cut-off concentration, 50 ng/ml, for example, is established, and a sample containing the standard concentration of analyte will be prepared. Unknowns that generate a stronger signal than the known sample are "positive". Those that generate weaker signal are "negative". There are ELISA tests to detect various kind of diseases, such as dengue, malaria, Chagas disease, Johne's disease, and others. ELISA tests also are extensively employed for in vitro diagnostics in medical laboratories. The other uses of ELISA include:
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.